{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:18:49Z","timestamp":1792167529705,"version":"4.4.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"publisher","award":["CO-JP-986-7009"],"award-info":[{"award-number":["CO-JP-986-7009"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the long-term safety and exploratory efficacy of filgotinib, a JAK1-preferential inhibitor, in patients with idiopathic multicentric Castleman disease (iMCD) over 52\u00a0weeks in a small, single-arm extension study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This Phase Ib single-arm extension study enroled five patients with iMCD who completed an initial 8\u00a0weeks\u2019 treatment with filgotinib. Patients received filgotinib 200\u00a0mg once daily for an additional 44\u00a0weeks (total 52\u00a0weeks). The primary endpoints assessed the comprehensive safety parameters. The secondary endpoints were efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All five patients completed the full 52-week treatment period without permanent discontinuation. No serious adverse events or deaths were observed. All adverse events were mild-to-moderate (Grade 1-2), with upper respiratory infections in four patients and headache in three of five patients. Herpes zoster occurred in one patient. At Week 52, three of five patients had \u22651-point CHAP score reduction (one additional patient compared with Week 8). Median changes from baseline included: C-reactive protein \u22121.85\u00a0mg\/dl, haemoglobin +0.50\u00a0g\/dl, albumin +0.30\u00a0g\/dl, and ECOG-PS zero points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Filgotinib was well-tolerated over 52\u00a0weeks with no serious adverse events reported. Numerical changes in disease activity markers were observed over time, providing preliminary support for the therapeutic concept of JAK inhibition in iMCD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roag011","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T12:44:08Z","timestamp":1771418648000},"page":"627-634","source":"Crossref","is-referenced-by-count":1,"title":["Long-term safety and efficacy of filgotinib in patients with idiopathic multicentric Castleman disease: 52-week results from a Phase Ib clinical trial"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5487-4692","authenticated-orcid":false,"given":"Shoichi","family":"Fukui","sequence":"first","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki ,","place":["Japan"]},{"name":"Clinical Research Center, Nagasaki University Hospital , Nagasaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Sumiyoshi","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki ,","place":["Japan"]},{"name":"Clinical Research Center, Nagasaki University Hospital , Nagasaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital , Nagasaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawana","family":"Narita","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital , Nagasaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital , Nagasaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Kamisawa","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital , Nagasaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Kiya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital , Nagasaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Katsube","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe , Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kato","sequence":"additional","affiliation":[{"name":"Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe , Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiko","family":"Kawamoto","sequence":"additional","affiliation":[{"name":"Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe , Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"2026070605220639800_ref1","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2013-12-545087","article-title":"HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy","volume":"123","author":"Fajgenbaum","year":"2014","journal-title":"Blood"},{"key":"2026070605220639800_ref2","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"key":"2026070605220639800_ref3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"Van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026070605220639800_ref4","first-page":"e78865","article-title":"A Phase Ib investigator-initiated trial of filgotinib in patients with idiopathic multicentric Castleman disease","volume":"17","author":"Fukui","year":"2025","journal-title":"Cureus"},{"key":"2026070605220639800_ref5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/14397595.2017.1366093","article-title":"Tentative diagnostic criteria and disease severity classification for Castleman disease: a report of the research group on Castleman disease in Japan","volume":"28","author":"Fujimoto","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2026070605220639800_ref6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"2026070605220639800_ref7","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026070605220639800_ref8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2026070605220639800_ref9","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease","volume":"96","author":"Nishimura","year":"2021","journal-title":"Am J Hematol"},{"key":"2026070605220639800_ref10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"2026070605220639800_ref11","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"Rhee","year":"2018","journal-title":"Blood"},{"key":"2026070605220639800_ref12","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a Phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"2026070605220639800_ref13","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/rheumatology\/kead552","article-title":"Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors","volume":"63","author":"K\u00e4llmark","year":"2024","journal-title":"Rheumatol"},{"key":"2026070605220639800_ref14","doi-asserted-by":"publisher","first-page":"104559","DOI":"10.1016\/j.jpain.2024.104559","article-title":"Measurement error, minimal detectable change, and minimal clinically important difference of the short Form-36 health survey, hospital anxiety and depression scale, and pain numeric rating scale in patients with chronic pain","volume":"25","author":"Gr\u00f6nkvist","year":"2024","journal-title":"J Pain"},{"key":"2026070605220639800_ref15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/pbc.29261","article-title":"Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6\/JAK inhibition: a pediatric case series","volume":"68","author":"Lust","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2026070605220639800_ref16","doi-asserted-by":"crossref","first-page":"e32200","DOI":"10.1097\/MD.0000000000032200","article-title":"Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: a case report","volume":"101","author":"Kakutani","year":"2022","journal-title":"Medicine"},{"key":"2026070605220639800_ref17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4274\/tjh.galenos.2024.2023.0477","article-title":"Ruxolitinib for the treatment of refractory idiopathic multicentric Castleman disease: a case report","volume":"41","author":"Gao","year":"2024","journal-title":"Turk J Haematol"},{"key":"2026070605220639800_ref18","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/art.40186","article-title":"Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK-1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized Phase IIa trials","volume":"69","author":"Vanhoutte","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026070605220639800_ref19","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1182\/bloodadvances.2020004016","article-title":"Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease","volume":"5","author":"Pierson","year":"2021","journal-title":"Blood Adv"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag011\/66989264\/roag011.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/627\/66989264\/roag011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/627\/66989264\/roag011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:22:34Z","timestamp":1783329754000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/4\/627\/8490291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2,19]]},"published-print":{"date-parts":[[2026,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roag011","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,2,19]]}}}